Novo Nordisk takes Forma’s sickle cell treatment into Phase 3
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study.
The Danish pharma company, known for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
